CompletedPhase 2

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

United States24 participantsStarted 2013-10

Plain-language summary

The standard treatment of surgery followed by radiation therapy can stop tumors from growing in the head and neck region in most patients. However, the cancer can recur or can spread to other parts of the body. Cetuximab is a drug that may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. It was approved by the United States Food and Drug Administration (FDA) in 2006 for the treatment of head and neck cancer. The purpose of this study is to determine how easily cetuximab can be added to treatment with radiation therapy in patients with cutaneous cancer of the head and neck. This study will also look at how well cetuximab added to radiation therapy works over time and how well this treatment is tolerated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pathologically (histologically) proven diagnosis of cutaneous squamous cell carcinoma of the head and neck * Clinical stage \>/= T3 or \>/= N1, M0 including no distant metastases * Gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration * Performance status of 0-1 within 2 weeks prior to registration * Age \>/= 18 * Adequate labs within 2 weeks prior to registration Exclusion Criteria: * Prior invasive malignancy unless disease free for a minimum of 3 years; noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated \< 3 years ago. Patients with a history of T1-2, N0, M0 resected differentiated thyroid carcinoma are considered eligible. * Prior systemic chemotherapy or anti-epidermal growth factor therapy for the study cancer or for a different prior cancer * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

What they're measuring

Percentage of Participants With Local Regional Control

Timeframe: 2 years

Trial details

NCT IDNCT01979211

SponsorUniversity of Cincinnati

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01-19

Results submitted2021-12-08